BioinvestGPT

BioinvestGPT ApS · Research use only

NCT03941093 (Pamrevlumab + Gemcitabine +… in Locally Advanced Pancreatic Cancer): BVCT ex-ante prediction vs. reported outcome

On 15 May 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 30 Jul 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT03941093
Acronym
LAPIS
Drug Name
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
Drug MoA
anti-CTGF mAb inhibitor
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Locally Advanced Pancreatic Cancer
Human Patients
284
Sponsor
FibroGen
Phase
Phase 3

Prediction of , index 456

Prospective Prediction
Prediction Index
456
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit in OS)
Technical Prediction
partial SUCCESS (statistically maybe significant additive clinical benefit in ORR/PFS)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
76 days in advance
Readout Data Interpretation
OS endpoint not met (p=0.55).
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Phase
Phase 3
Status
Completed
Enrollment
284
Lead sponsor
Kyntra Bio
Conditions
Pancreatic Cancer Non-resectable
Interventions
DRUG: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX; DRUG: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2019-05-10
Primary completion
2024-06-11
Completion
2024-06-11
Results first posted
2024-11-05
Primary outcomes
  • Overall Survival (Up to approximately 5 years)

NCT03941093 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials